The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans

Despite the success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines, there remains a need for more prevention and treatment options for individuals remaining at risk of coronavirus disease 2019 (COVID-19). Monoclonal antibodies (mAbs) against the viral spike protein have pot...

Descripción completa

Detalles Bibliográficos
Autores principales: Loo, Yueh-Ming, McTamney, Patrick M., Arends, Rosalinda H., Abram, Michael E., Aksyuk, Anastasia A., Diallo, Seme, Flores, Daniel J., Kelly, Elizabeth J., Ren, Kuishu, Roque, Richard, Rosenthal, Kim, Streicher, Katie, Tuffy, Kevin M., Bond, Nicholas J., Cornwell, Owen, Bouquet, Jerome, Cheng, Lily I., Dunyak, James, Huang, Yue, Rosenbaum, Anton I., Reddy, Venkatesh Pilla, Andersen, Hanne, Carnahan, Robert H., Crowe, James E., Kuehne, Ana I., Herbert, Andrew S., Dye, John M., Bright, Helen, Kallewaard, Nicole L., Pangalos, Menelas N., Esser, Mark T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8939769/
https://www.ncbi.nlm.nih.gov/pubmed/35076282
http://dx.doi.org/10.1126/scitranslmed.abl8124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8939769/
https://www.ncbi.nlm.nih.gov/pubmed/35076282
http://dx.doi.org/10.1126/scitranslmed.abl8124

Ejemplares similares